©The Author(s) 2015.
World J Gastroenterol. Mar 21, 2015; 21(11): 3291-3299
Published online Mar 21, 2015. doi: 10.3748/wjg.v21.i11.3291
Published online Mar 21, 2015. doi: 10.3748/wjg.v21.i11.3291
Table 1 Demographic and clinical characteristics of the patients
| Number of patients | 100 |
| SVR/non-SVR | 63/37 |
| Age (yr) | 56.3 ± 7.4 |
| Male/female | 39/61 |
| Genotype (1b/2a/2b) | 50/17/33 |
| HCV RNA (log IU/mL) | 5.87 ± 0.95 |
| Aspartate aminotransferase (< 30 IU/L) | 51.1 ± 35.9 |
| Alanine aminotransferase (< 30 IU/L) | 61.8 ± 53.0 |
| γ-glutamyl transpeptidase (< 50 IU/L) | 50.7 ± 58.9 |
| Fe (male, 55-200 μg/dL; female, 45-180 μg/dL) | 130.3 ± 64.2 |
| Unsaturated iron binding capacity (105-300 μg/dL) | 215.1 ± 84.2 |
| WBC (4000-9000/μL) | 4987 ± 1303 |
| Hemoglobin (male, 13-17; female, 11-15 g/dL) | 13.6 ± 1.5 |
| Platelet (11 × 104-35 × 104/μL) | 19.6 ± 6.7 |
| Dose reduction of ribavirin (%) | 47 |
- Citation: Kohjima M, Yoshimoto T, Enjoji M, Fukushima N, Fukuizumi K, Nakamura T, Kurokawa M, Fujimori N, Sasaki Y, Shimonaka Y, Murata Y, Koyama S, Kawabe K, Haraguchi K, Sumida Y, Harada N, Kato M, Kotoh K, Nakamuta M. Hepcidin/ferroportin expression levels involve efficacy of pegylated-interferon plus ribavirin in hepatitis C virus-infected liver. World J Gastroenterol 2015; 21(11): 3291-3299
- URL: https://www.wjgnet.com/1007-9327/full/v21/i11/3291.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i11.3291